Phase 2 N=227 A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Prostate Cancer
Primary: Time to Prostate Cancer Progression — NA; NA Months — p=0.016
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Number of Participants With Adverse Events — 5; 3; 28 Participants
Phase 2 N=47 Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
Peanut Allergy
Primary: Number of Participants With Treatment-related Adverse Events and Dosing Symptoms Occurring With Peanut OIT Over a Protracted Treatment Period Comprising at Least 18…
Phase 2 N=445 Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Chikungunya Virus Infection
Primary: Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8. — 2057.0; 1116.2; 1465.3; 2023.8 titer — p=0.0015
Phase 2 N=50 Crizanlizumab for Treating COVID-19 Vasculopathy
COVID-19
Primary: Soluble P-selectin Level — 7; 39 ng/mL
Phase 2 N=25 Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Time From Initiation of Adjunctive Therapy Until Hospital Discharge — 20; 33.8 Days
Phase 2 N=66 Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
Acute Leukemia
Primary: Number of Participants With Proven/Probable/Possible Invasive Fungal Infection — 1; 0; 2; 62 Participants
Phase 2 N=43 Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Confirmed Best Objective Response (BOR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 Assessed by…
Phase 2 N=22 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants
Phase 2 N=41 Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate — 29.3 percentage of participants
Phase 2 N=12 Dose Finding Safety Study of VAL201 in Cancer Patients
Stage III Prostate Carcinoma · Stage IV Prostate Carcinoma
Primary: Dose-Limiting Toxicity — 0; 0; 0; 0 Participants
Phase 2 N=29 Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Primary: Objective Response Rate (ORR) — 4 percentage of participants
Phase 2 N=6 A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline up to 8 Weeks Treatment — 5 Participants
Phase 2 N=165 Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
Arthritis, Psoriatic
Primary: Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20) — 29.3; 46.3; 52.4; 39.0 percentage of participants
Phase 2 N=70 Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Safety and Tolerability of MN-166 60 mg/d Versus Placebo When Administered With Riluzole in Subjects With ALS — 17; 34; 8; 11 Participants